Table 3. Risk of Incident Type 2 Diabetes According to Cumulative Duration and Cumulative Dose Among Youths Insured by Medicaid (5-20 Years of Age) Who Initiated Treatment With Antidepressant Medications, 2005-2009.
| Exposure Status | Person-Months | Cases, No. | Absolute Risk per 10 000 Person-Months |
Adjusted Relative Risk (95% CI)a |
|---|---|---|---|---|
| Among Current Users of SSRIs or SNRIs | ||||
| Cumulative duration, d | ||||
| 1-90 | 380 416 | 20 | 0.53 | 1 [Reference] |
| 91-150 | 122 031 | 13 | 1.07 | 1.68 (0.83-3.40) |
| 151-210 | 83 246 | 15 | 1.80 | 2.56 (1.29-5.08) |
| >210 | 277 597 | 63 | 2.27 | 2.66 (1.45-4.88) |
| Cumulative dose, mgb | ||||
| 1-1500 | 358 385 | 19 | 0.53 | 1 [Reference] |
| 1501-3000 | 148 939 | 12 | 0.81 | 1.22 (0.59-2.52) |
| 3001-4500 | 85 822 | 14 | 1.63 | 2.17 (1.07-4.40) |
| >4500 | 270 144 | 66 | 2.44 | 2.44 (1.35-4.43) |
| Among Current Users of Other Antidepressants | ||||
| Cumulative duration, d | ||||
| 1-90 | 182 812 | 20 | 1.09 | 1 [Reference] |
| 91-210 | 90 342 | 15 | 1.66 | 1.36 (0.68-2.73) |
| >210 | 126 097 | 11 | 0.87 | 0.74 (0.30-1.82) |
| Cumulative dose, mgb | ||||
| 1-1500 | 202 735 | 20 | 0.99 | 1 [Reference] |
| 1501-4500 | 102 674 | 14 | 1.36 | 1.33 (0.65-2.72) |
| >4500 | 93 842 | 12 | 1.28 | 1.37 (0.58-3.24) |
Abbreviations: SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.
a
All regression models were adjusted for disease risk score (expressed as percentile ranks), time from cohort entry (ie, follow-up month), and exposure to tricyclic and other related cyclic antidepressants. In youths currently using SSRIs or SNRIs, the use of other antidepressants was also adjusted. Likewise, in youths currently using other antidepressants, the use of SSRIs or SNRIs was also adjusted.
b
The cumulative dose was calculated in fluoxetine hydrochloride equivalents.